Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: Pfizer bullish on its oral glp-1; BMS’s rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam’s CETP inhibitor shows promise; and a look at Mankind’s Bharat Serums buy.  

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

More from Alimentary/Metabolic

More from Therapy Areas